About Rivaroxaban API

Therapeutic CategoryCardiovascular
API Technology
Synthetic
Dose Form
Oral Solid/Tablets
Dr Reddy's Development Status
Available (Commercial)
Available Regulatory Filing
USDMF, CEP Submitted, Brazil DMF, Canada DMF, Russia DMF
Mechanism of Action
XARELTO is a selective inhibitor of FXa. It does not require a cofactor (such as Anti-thrombin III) for activity. Rivaroxaban inhibits free FXa and prothrombinase activity. Rivaroxaban has no direct effect on platelet aggregation, but indirectly inhibits platelet aggregation induced by thrombin. By inhibiting FXa, rivaroxaban decreases thrombin generation.
Indication
XARELTO is a factor Xa inhibitor indicated:
- To reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation
- For the treatment of deep vein thrombosis (DVT)
- For the treatment of pulmonary embolism (PE)
- For the reduction in the risk of recurrence of DVT and/or PE in patients at continued risk for recurrent DVT and/or PE after completion of initial treatment lasting at least 6 months
- For the prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery
Dr. Reddy's Expertise
Headquartered in Hyderabad, India, Dr. Reddy's Laboratories is one of the leading Active Pharmaceutical Ingredients (API) manufacturers and suppliers globally for Rivaroxaban API. Dr. Reddy's API business is a preferred partner to pharma companies across the US, Europe, Brazil, Latin America, Japan, China, Korea, Middle East and other emerging markets.
Dr. Reddy's API business thrives on the deep technical strengths established over the last 30+ years in the development and manufacture of complex APIs such as steroids, peptides, complex long chain molecules and highly potent APIs (HPAPIs / oncology drugs). This expertise is complemented by our prowess in intellectual property and regulatory affairs which helps us consistently meet and exceed regulatory standards. Dr. Reddy's Rivaroxaban API is the outcome of the extensive expertise in R&D, IP, and Regulatory.
A key component in helping our customers be first to market is a responsive supply chain. We achieve this by making sure that all our facilities are operating efficiently and to the latest standards of quality, safety, and productivity. A strong interconnect between business and factories allows for a quick reaction to dynamic market changes, so that we can avert shortages and meet sudden surges in demand.
RFQ Form
Related Resources
FAQs
It is a cardiovascular drug used to treat Nonvalvular atrial fibrillation, deep vein thrombosis, pulmonary embolism.
The safety dose for Rivaroxaban is 2.5, 10, 15 & 20 mg
Circulating levels of rivaroxaban based on its anticoagulant action.
We offer Form-I of Rivaroxaban API
Meet with our product experts in one-on-one virtual sessions at https://api.drreddys.com/meet-api-experts or Write to us at [email protected].